Available Forms: Injection
Available Strengths: 150 mg/6 mL
Reference Brands: Briumvi (USA/EU)
Category: Neurology
ublituximab-xiyl is a CD20-directed monoclonal antibody that targets B-cells responsible for nerve damage in multiple sclerosis. It helps reduce relapses and slow disability progression in adults with relapsing forms of MS. Administered as an intravenous infusion, it offers a targeted approach with fewer infusion sessions compared to some other MS therapies. ublituximab-xiyl is available in Injection and strengths such as 150 mg/6 mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, ublituximab-xiyl is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
ublituximab-xiyl can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Quick Response Guaranteed | Verified Suppliers
Strength: 125 mg/mL, 200 mg, 250 mg, 300 mg, 500 mg, 100 mg/mL
Form: Tablet / Capsule/ Injection / Oral syrup
Reference Brands: Depakene (USA), Depakine (EU/LATAM), Valprol (India)
Strength: 50 mg, 100 mg
Form: Tablets
Reference Brands: Ubrelvy (USA/India)
Strength: 100 mg
Reference Brands: Tasmar (USA/EU)
Strength: 50 mg ,100 mg
Reference Brands: Xadago (USA/EU)
By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under ‘Fair use.’
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Stay updated on pharma trends and marketplace opportunities.